ArticleThe journal of liquid biopsy2025
Implementation of circulating tumor DNA (ctDNA) testing in precision oncology: A four-year experience from a tertiary cancer center in India.
Article in The journal of liquid biopsy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advanced gastroesophageal junction adenocarcinoma with skin involvement: a multidisciplinary perspective.Oxford medical case reports · 2026Article
- Diagnostic Pathways and Molecular Biomarkers in Colorectal Cancer: Current Evidence and Perspectives in Poland.Current issues in molecular biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Liquid biopsy testing has emerged as a pivotal tool in molecular characterization of solid malignancies. Circulating tumor DNA (ctDNA) analysis is quintessential in precision oncology for early detection, disease monitoring, prognosis, and theranostic purposes. This study summarizes ctDNA analysis performed on patients with advanced or metastatic solid tumors at tertiary cancer centers in India (2021-2024). Methods: ctDNA was isolated following standard pre-analytical protocols and quality control measures. Sequencing was performed using the Oncomine Precision Assay on Thermo Fisher platform and Custom Solid Tumor Panel (SOPHiA Genetics) on Illumina platforms. Variant annotation and clinical interpretation were performed as per ACMG and AMP Guidelines. Results: Out of 236 ctDNA samples, majority were lung malignancies (47 %), gastric cancers (43 %), head & neck cancers (2 %), other malignancies (8 %). A total of 250 clinically relevant genomic alterations were reported. On Illumina, 19.8 % of variants were classified as Tier I, 18.3 % Tier II, and 11.7 % as Tier III. Thermofisher platform identified Tier I alterations in 33 %, Tier II in 54 %, and Tier III in 11 % cases. In the GI cohort, Conclusion: Study underscores substantial increase in the adoption of liquid biopsy and the real-world utility of ctDNA-based NGS testing in solid tumors contributing to improved patient care management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.